Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Health services and systems news

Show

From To
Hillary Clinton calls out drug maker Gilead over price of hepatitis C pills

Democratic presidential nominee Hillary Clinton said Wednesday her administration will go after drug companies that charge exorbitant prices, singling out the company Gilead, whose hepatitis C drugs cost between $900 and $1,000 per pill in the United States.

Published
19 August 2016
From
UPI.com
German agency criticises European programme for speeding some drug approvals

In pointed remarks, Germany’s cost-effectiveness watchdog has criticised an effort by European regulators to accelerate approval for new medicines by limiting its requirements for evidence. The concerns raised by the agency come as regulators on both side of the Atlantic increasingly look to such approaches to get new drugs to patients with unmet medical needs. At issue is a proposal called adaptive pathways, a term used to describe a method for jumpstarting drug approvals for select patient populations. Two years ago,an EMA pilot programme was launched to compare initial data used for approval with so-called “real world” data, which is subsequently gathered after the medicines are in use.

Published
18 August 2016
From
STAT
Today In History, 1990: President George H.W. Bush Signs the Ryan White CARE Act

Since the earliest days of the AIDS epidemic, the nation’s response to the deadly disease was chronically slow and woefully underfunded. Much of the resistance to increased funding stemmed from open hostility to the disease’s two main risk groups; gay men and intravenous drug users.

Published
18 August 2016
From
Box Turtle Bulletin
Cancer drug companies cut prices to win NHS approval

Tougher new policy by regulator means pharma firms are having to offer better value for money to get treatments accepted by NHS.

Published
18 August 2016
From
The Guardian
ViiV Healthcare launches phase III programme evaluating a two-drug regimen combining dolutegravir and lamivudine for HIV-1 treatment

The phase III programme comprises two identical studies (GEMINI 1 and 2) comparing a two-drug regimen of dolutegravir plus lamivudine with a three-drug regimen of dolutegravir plus the fixed-dose tablet tenofovir/emtricitabine (Truvada®), as treatment for HIV-1 infection in adults who have not received prior antiretroviral therapy.

Published
16 August 2016
From
ViiV press release
The end of the end of AIDS

The Durban 2016 AIDS Conference marks the end of "ending the HIV epidemic" as a feasible goal with the tools we have. We need new and better tools. Talk of ending AIDS has led to a widespread perception in the broader health and development community that this crisis is over. It isn't.

Published
16 August 2016
From
World Bank (blog)
Have your say on PrEP – Londoners urged to voice their opinions

Londoners are being urged to share their views and opinions on PrEP with NHS England. Councillor Teresa O’Neill OBE, London Councils’ Executive member for health, stressed the importance of Londoners sharing their views as a large portion of those living with HIV reside in the capital. “We are concerned that NHS England, by arguing it is not responsible for funding PrEP, is trying to shift costs to local authorities."

Published
16 August 2016
From
Gay Times
Are we losing our passion as AIDS activists?

We’ve come a long way since the days when fighting for LGBT rights demanded action such as the Stonewall Riots. Or a critical need for HIV medications prompted protests blocking traffic on the Golden Gate Bridge. Are we finished? Have the communities and people affected by HIV and AIDS fought hard enough, and is the job of AIDS activists near an end?

Published
16 August 2016
From
BETA blog
As Trump Vice President, Mike Pence Would Be a Nightmare for People With HIV

There is nothing in Mike Pence's statements or actions to suggest that he has learned anything from the HIV outbreak that ran rampant through Scott County, Indiana, when he governed the state. As one indication of his HIV priorities, his advocacy for LGBT conversion therapy while in the U.S. House of Representatives included proposing that the Ryan White Care Act be reauthorized only if monies were redirected towards organizations "which provide assistance to those seeking to change their sexual behavior."

Published
15 August 2016
From
The Body
Gilead bags Genmab tech to develop bispecific antibody against HIV

Gilead has struck a deal to access bispecific antibody technology from Genmab. The agreement gives Gilead an exclusive license to use the Danish drugmaker’s bispecific platform to create an HIV therapeutic, plus an option to take up another exclusive license on the technology.

Published
12 August 2016
From
FierceBiotech

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close